Abstract 2313P
Background
APOBEC enzymes play key roles in DNA editing and are highly expressed in various cancer types, including estrogen receptor (ER)+/HER2- breast cancer (BC). APOBEC enzyme activation promotes mutagenesis that results in the generation of neoantigens, potentially leading to an anti-tumor immune response. APOBEC mutagenesis has been associated to resistance to chemotherapy and immunotherapy. The impact of APOBEC mutagenesis on the tumor microenvironment (TME) still remains unclear. Here we sought to characterize the TME of ER+/HER2- BC displaying APOBEC mutagenesis and to validate the findings in other APOBEC-related cancer types.
Methods
ER+/HER2- BCs from TCGA with available whole exome and RNA-sequencing data were included (n=519). We inferred single base substitutions (SBS) mutational signatures using SigProfiler. Cell type fractions were computed using CIBERSORT. The correlation between APOBEC signatures (SBS signatures 2 and 13) and the abundance of TME cell types was defined using a logistic regression model adjusted by tumor mutation burden. False discovery rate correction was applied (q-value). Other APOBEC-related cancers (bladder, head and neck, cervix and uterine) were assessed.
Results
Of 519 ER+/HER2- BCs, 57 (11%) were classified as APOBEC-dominant, 84 (16%) as non-dominant-APOBEC and the remaining 378 (73%) as non-APOBEC. Compared to non-APOBEC, APOBEC-dominant ER+/HER2- BCs displayed an enrichment for macrophages M1 infiltration (q=0.026), and decreased macrophage M2 population (q=0.017). Non-dominant APOBEC BCs displayed an extent of macrophage M1 and M2 infiltration intermediate between the other two groups. Analysis of the TME composition according to APOBEC mutagenesis in bladder (n=389), head and neck (n=463), cervical (n=269) and uterine (n=474) cancers revealed differences comparable to those observed in ER+/HER2- BCs.
Conclusions
An association between APOBEC mutagenesis and macrophages M1 infiltration was observed, suggesting that APOBEC processes may uniquely shape the TME in cancer. Going forward, we will investigate the impact of other mutagenesis processes, such as homologous recombination deficiency (HRD), on the TME, to gain a comprehensive understanding of the interplay between various mutational processes and the TME.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Breast cancer research foundation and National Institutes of Health/National Cancer Institute.
Disclosure
B. Weigelt: Financial Interests, Institutional, Research Funding: Repare Therapeutics. J.S. Reis-Filho: Financial Interests, Personal, Other, Consultant: Goldman Sachs, Eli Lilly, Saga Diagnostics; Financial Interests, Personal, Other, Member of the Scientific Advisory Board and Consultant: Repare Therapeutics, Paige.AI; Financial Interests, Personal, Advisory Board: Personalis, Roche Tissue Diagnostics; Financial Interests, Personal, Advisory Board, Member of the Scientific Advisory Board: Bain Capital; Financial Interests, Personal, Advisory Board, Ad hoc member of the Pathology Scientific Advisory Board: Daiichi Sankyo, Merck; Financial Interests, Personal, Advisory Board, Ad hoc member of the Oncology Scientific Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board, Member of the SAB: MultiplexDX; Financial Interests, Personal, Member of Board of Directors: Odyssey Bio, Grupo Oncoclinicas; Financial Interests, Personal, Stocks/Shares: Repare Therapeutics; Financial Interests, Personal, Other, Stock options: Paige.AI. S. Chandarlapaty: Financial Interests, Personal, Other, Consultant: Novartis, Boxer Capital, Nuvalent, Inivata, Neogenomics; Financial Interests, Institutional, Research Grant: Daiichi Sankyo; Financial Interests, Personal and Institutional, Research Grant, Consultant: AstraZeneca; Financial Interests, Personal, Officer, Officer and Shares: Odyssey Biosciences; Financial Interests, Personal, Stocks/Shares: Totus Medicines. All other authors have declared no conflicts of interest.
Resources from the same session
2262P - Baseline-informed versus tumor-agnostic minimal residual disease (MRD) concordance study in patients with HER2+ gastroesophageal adenocarcinoma patients
Presenter: Pan Du
Session: Poster session 08
2263P - Ethnicity-specific distribution of BRCA1, BRCA2, PALB2 and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus
Presenter: Evgeny Imyanitov
Session: Poster session 08
2264P - Proteomics-based phenotypic classification of non-smallcell lung cancer
Presenter: Olena Berkovska
Session: Poster session 08
2265P - miR-4487 enhances gefitinib-mediated ubiquitination and autophagic degradation of EGFR in non-small cell lung cancer cells by targeting USP37
Presenter: Sei-Hoon Yang
Session: Poster session 08
2266P - IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort
Presenter: Marie Morfouace
Session: Poster session 08
2267P - Coronary heart disease and risk of lung cancer: A two-sample Mendelian randomization study
Presenter: Cai Chen Li
Session: Poster session 08
2269P - Patient derived xenografts generated from circulating cancer stem cells on chorioallantoic membrane as an alternative pre-clinical model for personalized medicine in pancreatic cancer
Presenter: Monika Pizon
Session: Poster session 08
2270P - Integrative analyses of bulk and single-cell RNA-seq identified diabetes mellitus-related signature as a prognostic factor in pancreatic adenocarcinoma
Presenter: Le Tang
Session: Poster session 08
2271P - Development of an oncolytic virus for the treatment of high grade serous ovarian cancer and other stromal rich tumours
Presenter: Miriam Bazan Peregrino
Session: Poster session 08
2272P - Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)
Presenter: Matteo Benelli
Session: Poster session 08